TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33476595
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery plus HIPEC (360 mg/m2 closed abdomen or 460 mg/m2 open abdomen)
Study: 32841748
Drug: Epicutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicutaneous immunotherapy (DBV712 250 μg, daily epicutaneous peanut protein)
Study: 35257614
Drug: Linear mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear mixed effects model with random treatment effects
Study: 35141396
Drug: 40 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 Hz transcranial alternating current stimulation (tACS) for 30 days, 1-hour daily sessions
Study: 34481729
Drug: Inhaled allergen-specific
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled allergen-specific IgE antibody positivity measurement
Study: 34481729
Drug: Specific IgE
Normalized name: BSA specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgE antibodies to inhaled allergens
Study: 32945537
Drug: Fenfluramine hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine hydrochloride (FFA), administered as add-on, twice daily at an initial dose of 0.2 mg/kg/d up to 0.7 mg/kg/d
Study: 33917677
Drug: Integrated oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated oral healthcare intervention (dental assistance and collective health education actions in conversation circles)
Study: 33596735
Drug: Daily tenofovir/emtricitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tenofovir/emtricitabine (TDF-FTC)
Study: 33444208
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg just before surgery and 600 mg/day for 2 days after surgery)
Study: 33043552
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg daily for 2 weeks)
Study: 33043552
Drug: Bisoprolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (up to 10 mg daily in open-label extension)
Study: 34387038
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg orally once at night for 3 days starting on postoperative day 1 (treatment group)
Study: 34387038
Drug: Non-treatment (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment (control group)
Study: 32096613
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day SC elamipretide for 4 weeks
Study: 32096613
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day SC elamipretide
Study: 33872573
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Massage Treatment (NPMT)
Study: 35338860
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy and placebo
Study: 36174096
Drug: PARADIES intervention
Normalized name: Citrus paradisi fruit oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARADIES intervention (combined cognitive behavioural therapy with case management)
Study: 34714130
Drug: 100 g dried
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g dried plum
Study: 34714130
Drug: Control (0 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g dried plum)
Study: 36202391
Drug: Mixed tree
Normalized name: ALLERGENIC EXTRACT MIXED TREES INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed tree nuts (30 g/d for 4 weeks)
Study: 33308469
Drug: ChAdOx1 nCoV‐19
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV‐19 vaccine
Study: 35641232
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposomal injection (VSLI) at 2.25 mg/m2
Study: 35641232
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposomal injection (VSLI) with bendamustine and rituximab (BR)
Study: 35641232
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposomal injection (VSLI)
Study: 34823572
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation treatment (twice-daily for two weeks)
Study: 34823572
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation treatment
Study: 32753447
Drug: Cinacalcet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet plus conventional therapy (cinacalcet strategy)
Study: 32753447
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (standard strategy)
Study: 36475294
Drug: liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 3 mg/day
Study: 37431849
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors
Study: 32991033
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEi)
Study: 36094625
Drug: Standard Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Treatment (SMT)
Study: 34146343
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (optimally effective)
Study: 34146343
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (improvement-type model)
Study: 34146343
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (adjusted for treatment discontinuation, remission-type model)
Study: 34146343
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (adjusted for treatment discontinuation, improvement-type model)
Study: 32297486
Drug: brexpiprazole 1
Normalized name: brexpiprazole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 1 mg/day, increased to 2 mg/day by week 4, up to 4 mg/day according to CGI-I criteria
Study: 35830641
Drug: Erythropoietin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (1000 U/kg) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Study: 35830641
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Study: 32077353
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy decisions under assumed ideal conditions
Study: 32077353
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy decisions under current local resources
Study: 34999737
Drug: Drug Recognition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Recognition Evaluator-conducted expanded field sobriety examination
Study: 36053616
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion of local anaesthetic (bupivacaine) for the first 72 hours along with systemic opioid analgesia (catheter group)
Study: 32243865
Drug: Landiolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (1 μg/kg per min, IV infusion, can be increased to a maximum of 20 μg/kg per min)
Study: 32243865
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional sepsis therapy)
Study: 32074684
Drug: Mosapride group
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride group (Mosapride citrate tablets 5 mg 3 times per day for 2 weeks)
Study: 32074684
Drug: Combizym(®) group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combizym(®) group (Combizym tablets 244 mg 3 times per day for 2 weeks)
Study: 32074684
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (both drugs at same doses for 2 weeks)
Study: 32807229
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine rehabilitation (IMR) with usual rehabilitation (UR)
Study: 35769368
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase treatment
Study: 35745123
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for wound treatment
Study: 32534040
Drug: Resveratrol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (250 mg/day)
Study: 33569986
Drug: FTD/TPI monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTD/TPI monotherapy
Study: 32482095
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g protein post-exercise
Study: 32482095
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g protein post-exercise
Study: 32266765
Drug: Therapy dog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy dog interaction for 5 minutes
Study: 32266765
Drug: Therapy dog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy dog interaction and coloring
Study: 33380580
Drug: Hydrogen inhalation
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen inhalation (66.7% hydrogen and 33.3% oxygen, 3 L/min for 4 hours each day for 2 weeks)
Study: 33166307
Drug: Intranasal GSK2245035
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GSK2245035 20 ng once weekly for 8 weeks
Study: 34491016
Drug: AbobotulinumtoxinA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA (all doses)
Study: 34501925
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health intervention (oral health assessment, dental treatment recommendations, oral health education)
Study: 35175218
Drug: Intranasal gel
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal gel with a bacteriophages mixture (Otofag, Micromir, Russia) twice a day for ten weeks
Study: 35538296
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 35 mg twice daily
Study: 32543020
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg orally daily
Study: 32543020
Drug: Furosemide 5
Normalized name: furosemide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 5 mg/h intravenously
Study: 36171101
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) before EVT
Study: 35462369
Drug: Desidustat oral
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat oral tablets (thrice a week) for 24 weeks
Study: 35462369
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa subcutaneous injection for 24 weeks
Study: 33067129
Drug: Fortified yogurt
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified yogurt with 3 g HMB, 1000 IU vitamin D, and 500 mg vitamin C
Study: 35871650
Drug: Time-restricted eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-restricted eating (TRE) for 3 weeks (daily food intake within 10 h)
Study: 34700294
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg sodium, two capsules per day for five days)
Study: 32274653
Drug: Peficitinib (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peficitinib (20, 60, or 200 mg)
Study: 32274653
Drug: Peficitinib (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peficitinib (10, 30, or 100 mg) twice daily for 7 days
Study: 35255229
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day empagliflozin (EMPA)
Study: 35255229
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (NOEMPA)
Study: 34275586
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg/day) and Temozolomide (50 mg/m2/day)
Study: 34487566
Drug: Low-energy CO2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-energy CO2 laser treatment
Study: 34653287
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) - two 15 mg/kg infusions 7 days apart; maximum dose, 750 mg single/1500 mg total
Study: 35708895
Drug: Nomogram based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram based on cumulative anthracycline dose, ejection fractions, NT-proBNP, and diastolic dysfunction.
Study: 32737585
Drug: Medical air
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical air (placebo) inhalation
Study: 34787005
Drug: Ofatumumab 20
Normalized name: ofatumumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 20 mg
Study: 34847676
Drug: Transcutaneous tibial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous tibial nerve stimulation (TTNS) daily for 3 months
Study: 34847676
Drug: Percutaneous tibial
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous tibial nerve stimulation (PTNS) weekly for 3 months
Study: 34125899
Drug: Standard-dose VitD/Ca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose VitD/Ca supplementation (400 IU/1200 mg/day) for 48 weeks
Study: 34125899
Drug: High-dose VitD/Ca
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VitD/Ca supplementation (400 IU/1200 mg/day plus ergocalciferol 20,000 IU/week) for 48 weeks
Study: 34125899
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Standard-dose and High-dose)
Study: 33624240
Drug: Anaerobically digested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaerobically digested swine manure at 25 g·kg‐1
Study: 33624240
Drug: Anaerobically digested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaerobically digested swine manure at 10 g·kg‐1
Study: 33624240
Drug: Anaerobically digested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaerobically digested swine manure at 0 g·kg‐1
Study: 34859788
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Mg as Mg citrate daily for 12 weeks
Study: 36247849
Drug: CT-guided percutaneous
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided percutaneous radiofrequency ablation therapy
Study: 35241351
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch adherence
Study: 35241351
Drug: Quit day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quit day smoking status, patch adherence, duration of abstinence, and percent negative CO samples submitted
Study: 36190380
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg per day for 12 weeks)
Study: 34291808
Drug: Digital Cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Cognitive Behavioral Therapy for Insomnia (dCBT‐I)
Study: 34291808
Drug: Face-to-face Cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face Cognitive Behavioral Therapy for Insomnia (FtF CBT‐I)
Study: 34193328
Drug: Mindfulness-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Therapy for Insomnia (MBTI)
Study: 32343001
Drug: Non-alginate antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-alginate antacid
Study: 35659713
Drug: Bupivacaine 0.2%
Normalized name: BUPivacaine 0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.2% (50 cc) sprayed through the laparoscopic port
Study: 35659713
Drug: Intra-abdominal bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-abdominal bicarbonate (5.7% dissolved in 1000 cc normal saline)
Study: 33577055
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice daily for 12 weeks)
Study: 34408055
Drug: Solution-focused brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution-focused brief therapy, up to six sessions over 3 months, offered immediately postrandomisation or after a delay of 6 months.
Study: 35507735
Drug: Bone grafting
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone grafting to buccal bone crest (BCG)
Study: 33153273
Drug: Financial hardship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial hardship treatment adherence
Study: 33407146
Drug: Independent predictors
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent predictors for antiviral therapy
Study: 34340839
Drug: Standard multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multimodal analgesic regimen
Study: 34735165
Drug: Nonmonetary reinforcers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmonetary reinforcers (e.g., delivery of meme/gif following self-reporting completion)
Study: 34735165
Drug: Daily self-reporting
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-reporting rates
Study: 36370991
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Psychological Intervention (PI) and Electroacupuncture (EA) 30 min, 5 times a week for 4 weeks, total of 12 weeks
Study: 35135601
Drug: Theraflu Daytime
Normalized name: Theraflu Daytime Severe Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theraflu Daytime Severe Cold and Cough powder for oral solution
Study: 616463935
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec in DUAL I
Study: 616463935
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec in DUAL II
Study: 36479955
Drug: Pharmacotherapy following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacotherapy following CBT
Study: 36479955
Drug: No pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacotherapy following CBT
Study: 35318844
Drug: Mexidol intravenously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol intravenously, 500 mg once daily for 14 days, followed by oral Mexidol FORTE 250, 750 mg per day for 60 days
Study: 35318844
Drug: Mexidol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol treatment
Study: 34341325
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 µg/kg for >10 min before anesthesia and during maintenance)
Study: 33451618
Drug: Enhanced counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced counseling on optimal analgesic use
Study: 36180905
Drug: Telehealth swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth swallowing therapy sessions
Study: 33071986
Drug: Gushen'antai pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gushen'antai pills (GSATP) 6 g, tid for 12 weeks
Study: 33071986
Drug: Gushen'antai pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gushen'antai pills (GSATP) 6 g, tid for 12 weeks (younger than 35 years)
Study: 32227755
Drug: Initial invasive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial invasive strategy (angiography and revascularization when feasible) plus medical therapy
Study: 32227755
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative strategy (medical therapy alone and angiography if medical therapy failed)
Study: 35945651
Drug: 5 raw
Normalized name: Pomegranates, Raw
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 raw eggs (∼30 g protein)
Study: 35945651
Drug: 5 boiled
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 boiled eggs (∼30 g protein)
Study: 35945651
Drug: Control breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control breakfast (∼5 g protein)
Study: 34262052
Drug: Microneedle patches
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle patches (MNPs)
Study: 34616361
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg imigliptin
Study: 34616361
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg imigliptin
Study: 34616361
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg alogliptin
Study: 34632933
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day standardized cranberry extract
Study: 34632933
Drug: 240 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/day standardized cranberry extract
Study: 34632933
Drug: Nitrofurantoin administration
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin administration
Study: 34907082
Drug: Ipatasertib treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib treatment